These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30322476)

  • 21. PET/MR in dementia and other neurodegenerative diseases.
    Barthel H; Schroeter ML; Hoffmann KT; Sabri O
    Semin Nucl Med; 2015 May; 45(3):224-33. PubMed ID: 25841277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional imaging of cognitive impairment in Parkinson's disease.
    Fitzpatrick T; Mattis P; Eidelberg D
    Clin EEG Neurosci; 2010 Jul; 41(3):119-26. PubMed ID: 20722344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain: positron emission tomography tracers beyond [¹⁸F]fluorodeoxyglucose.
    Singhal T; Alavi A; Kim CK
    PET Clin; 2014 Jul; 9(3):267-76. PubMed ID: 25030390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in the development of tau PET radiotracers and their clinical applications.
    Okamura N; Harada R; Furukawa K; Furumoto S; Tago T; Yanai K; Arai H; Kudo Y
    Ageing Res Rev; 2016 Sep; 30():107-13. PubMed ID: 26802556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Nuclear medicine imaging in neurodegenerative dementias].
    Gratz S; Hahn U; Kaiser JW; Jarnig M; Schwarz J; Förstl H
    Dtsch Med Wochenschr; 2008 May; 133 Suppl 1():S5-7. PubMed ID: 18437639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.
    Perani D; Cerami C; Caminiti SP; Santangelo R; Coppi E; Ferrari L; Pinto P; Passerini G; Falini A; Iannaccone S; Cappa SF; Comi G; Gianolli L; Magnani G
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):499-508. PubMed ID: 26341365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of molecular imaging on the diagnostic process in a memory clinic.
    Ossenkoppele R; Prins ND; Pijnenburg YA; Lemstra AW; van der Flier WM; Adriaanse SF; Windhorst AD; Handels RL; Wolfs CA; Aalten P; Verhey FR; Verbeek MM; van Buchem MA; Hoekstra OS; Lammertsma AA; Scheltens P; van Berckel BN
    Alzheimers Dement; 2013 Jul; 9(4):414-21. PubMed ID: 23164552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The importance of molecular imaging (PET) in the diagnostics of dementia].
    Tscheuschler M; Gebest M; Jessen F; Drzezga A
    Nervenarzt; 2018 Jul; 89(7):843-856. PubMed ID: 29916030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography.
    Hansen AK; Damholdt MF; Fedorova TD; Knudsen K; Parbo P; Ismail R; Østergaard K; Brooks DJ; Borghammer P
    Mov Disord; 2017 Jun; 32(6):922-927. PubMed ID: 28256006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers for dementia and mild cognitive impairment in Parkinson's disease.
    Delgado-Alvarado M; Gago B; Navalpotro-Gomez I; Jiménez-Urbieta H; Rodriguez-Oroz MC
    Mov Disord; 2016 Jun; 31(6):861-81. PubMed ID: 27193487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Molecular imaging of cerebral blood flow and metabolism with SPET and PET in principal dementias].
    Gerasimou G; Bostantjopoulou S; Gotzamani-Psarrakou A
    Hell J Nucl Med; 2009; 12(1):79-83. PubMed ID: 19330195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The correlation between striatal and cortical binding ratio of
    Sauerbeck J; Ishii K; Hosokawa C; Kaida H; Scheiwein FT; Hanaoka K; Rominger A; Brendel M; Bartenstein P; Murakami T
    Ann Nucl Med; 2018 Jul; 32(6):398-403. PubMed ID: 29730823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Characteristics of cerebral glucose metabolism in patients with cognitive impairment in Parkinson's disease].
    Homenko JG; Susin DS; Kataeva GV; Irishina JA; Zavolokov IG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(5):46-51. PubMed ID: 28638030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longer-Term Investigation of the Value of 18F-FDG-PET and Magnetic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer's Disease: A Multicenter Study.
    Inui Y; Ito K; Kato T;
    J Alzheimers Dis; 2017; 60(3):877-887. PubMed ID: 28922157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.
    Rabinovici GD; Karlawish J; Knopman D; Snyder HM; Sperling R; Carrillo MC
    Alzheimers Dement; 2016 Apr; 12(4):510-5. PubMed ID: 27103054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging.
    Silverman DH
    J Nucl Med; 2004 Apr; 45(4):594-607. PubMed ID: 15073255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography.
    Brooks DJ
    Mov Disord; 2009; 24 Suppl 2():S742-7. PubMed ID: 19877240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early differential diagnosis between Alzheimer's disease and dementia with Lewy bodies: Comparison between (18)F-FDG PET and (123)I-IMP SPECT.
    Chiba Y; Iseki E; Fujishiro H; Ota K; Kasanuki K; Suzuki M; Hirayasu Y; Arai H; Sato K
    Psychiatry Res Neuroimaging; 2016 Mar; 249():105-12. PubMed ID: 26857415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
    Garibotto V; Herholz K; Boccardi M; Picco A; Varrone A; Nordberg A; Nobili F; Ratib O;
    Neurobiol Aging; 2017 Apr; 52():183-195. PubMed ID: 28317648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.